IJSR - International Journal of Scientific Research

Volume : VII, Issue : VII, July - 2018

Dr. Suneet Jindal, Dr. Ekta Arora

INTRODUCTION : Pulmonary tuberculosis is one of the largest causes of deaths due to infections worldwide. WHO recognizes India as one of

the 22 high–burden countries (HBC‘s) that account for about 80% of the world‘s TB cases. The evidence for role of Vitamin D3 on the course of

tubercular disease is inconclusive and different studies show both favorable and unfavorable responses. No data is available on dose–dependent

effects of vitamin D3 on mycobacterial activity.

MATERIAL AND METHODS: A prospective, randomized, interventional study of 90 days duration was conducted by dividing 60 newly

diagnosed sputum positive pulmonary tuberculosis Category I patients of either sex with age ≥16 years in two groups i.e

Group A receiving standard Anti–tubercular therapy in combination with

Vitamin D3 600,000IU intramuscularly on Day 0, 30 and 60 and Group B receiving standard Anti–tubercular therapy (DOTS regime) alone.

RESULTS: Out of 60 subjects enrolled in the present study, 39 (65%) patients were from urban, and 21 (35%) patients were from rural population.

All the patients enrolled in the study belonged to Below Poverty Line (BPL) group. In Group A and Group B, there was statistically significant

increase in mean difference in body weight at 30, 60 and 90 days from the baseline within the groups. No difference was found in 0 to 90 days

among Group A and Group B. There was statistically significant increase in Vitamin D levels in Group A only on 90 days. At 90 days, there was

significant difference in Vitamin D levels between Group A and Group B.